Logo image of DNA

GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Price, Quote, News and Overview

NYSE:DNA - New York Stock Exchange, Inc. - US37611X2099 - Common Stock - Currency: USD

7.04  +0.08 (+1.15%)

After market: 7.1596 +0.12 (+1.7%)

DNA Quote, Performance and Key Statistics

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (5/2/2025, 8:04:00 PM)

After market: 7.1596 +0.12 (+1.7%)

7.04

+0.08 (+1.15%)

Sector
GICS SectorMaterials
GICS IndustryChemicals
GICS IndustryGroupMaterials
GICS SubIndustrySpecialty Chemicals
Statistics
52 Week High41.2
52 Week Low5
Market Cap387.41M
Shares55.03M
Float42.03M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO04-19 2021-04-19


DNA short term performance overview.The bars show the price performance of DNA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

DNA long term performance overview.The bars show the price performance of DNA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of DNA is 7.04 USD. In the past month the price increased by 23.51%. In the past year, price decreased by -81.57%.

GINKGO BIOWORKS HOLDINGS INC / DNA Daily stock chart

DNA Competitors/Peers

The largest stocks on the US markets in the "Specialty Chemicals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
SHW SHERWIN-WILLIAMS CO/THE 31.52 90.13B
ECL ECOLAB INC 37.45 72.43B
DD DUPONT DE NEMOURS INC 16.52 28.14B
PPG PPG INDUSTRIES INC 13.88 25.08B
IFF INTL FLAVORS & FRAGRANCES 18.39 20.22B
RPM RPM INTERNATIONAL INC 21.46 14.17B
SQM QUIMICA Y MINERA CHIL-SP ADR N/A 9.71B
EMN EASTMAN CHEMICAL CO 9.51 9.00B
AXTA AXALTA COATING SYSTEMS LTD 14.8 7.23B
ALB ALBEMARLE CORP N/A 7.09B
NEU NEWMARKET CORP 12.5 5.92B
BCPC BALCHEM CORP 35.42 5.28B

About DNA

Company Profile

DNA logo image Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Company Info

GINKGO BIOWORKS HOLDINGS INC

27 Drydock Avenue, 8th Floor

Boston MASSACHUSETTS US

CEO: Harry E. Sloan

Employees: 1218

Company Website: https://investors.ginkgobioworks.com/

Investor Relations: https://investors.ginkgobioworks.com/

Phone: 18774425362

GINKGO BIOWORKS HOLDINGS INC / DNA FAQ

What is the stock price of GINKGO BIOWORKS HOLDINGS INC today?

The current stock price of DNA is 7.04 USD. The price increased by 1.15% in the last trading session.


What is the ticker symbol for GINKGO BIOWORKS HOLDINGS INC stock?

The exchange symbol of GINKGO BIOWORKS HOLDINGS INC is DNA and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is DNA stock listed?

DNA stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for GINKGO BIOWORKS HOLDINGS INC stock?

13 analysts have analysed DNA and the average price target is 8.47 USD. This implies a price increase of 20.26% is expected in the next year compared to the current price of 7.04. Check the GINKGO BIOWORKS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GINKGO BIOWORKS HOLDINGS INC worth?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a market capitalization of 387.41M USD. This makes DNA a Small Cap stock.


How many employees does GINKGO BIOWORKS HOLDINGS INC have?

GINKGO BIOWORKS HOLDINGS INC (DNA) currently has 1218 employees.


What are the support and resistance levels for GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a support level at 7.03 and a resistance level at 7.37. Check the full technical report for a detailed analysis of DNA support and resistance levels.


Is GINKGO BIOWORKS HOLDINGS INC (DNA) expected to grow?

The Revenue of GINKGO BIOWORKS HOLDINGS INC (DNA) is expected to decline by -24.02% in the next year. Check the estimates tab for more information on the DNA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GINKGO BIOWORKS HOLDINGS INC (DNA) stock pay dividends?

DNA does not pay a dividend.


What is the Price/Earnings (PE) ratio of GINKGO BIOWORKS HOLDINGS INC (DNA)?

GINKGO BIOWORKS HOLDINGS INC (DNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.94).


What is the Short Interest ratio of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

The outstanding short interest for GINKGO BIOWORKS HOLDINGS INC (DNA) is 31.74% of its float. Check the ownership tab for more information on the DNA short interest.


DNA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to DNA. When comparing the yearly performance of all stocks, DNA is a bad performer in the overall market: 97.34% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DNA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to DNA. DNA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DNA Financial Highlights

Over the last trailing twelve months DNA reported a non-GAAP Earnings per Share(EPS) of -8.94. The EPS increased by 52.45% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.71%
ROE -76.39%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%54.55%
Sales Q2Q%26.16%
EPS 1Y (TTM)52.45%
Revenue 1Y (TTM)-9.71%

DNA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to DNA. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 30.75% and a revenue growth -24.02% for DNA


Ownership
Inst Owners70.98%
Ins Owners6.65%
Short Float %31.74%
Short Ratio8.05
Analysts
Analysts43.08
Price Target8.47 (20.31%)
EPS Next Y30.75%
Revenue Next Year-24.02%